Search

Search Constraints

You searched for: Author/Creator Zer, Alona

Search Results

1. ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data. (28th January 2022)

2. Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real‐world evidence. Issue 5 (16th September 2020)

4. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Issue 7 (July 2019)

5. BIOM-01. TYROSINE KINASE INHIBITORS AS A TREATMENT OF SYMPTOMATIC CNS METASTASES IN ONCOGENE-DRIVEN NSCLC. (9th November 2020)

7. Characteristics of lung cancer in idiopathic pulmonary fibrosis with single lung transplant versus non-transplanted patients: a retrospective observational study. Issue 1 (21st June 2020)

8. Characteristics of lung cancer in idiopathic pulmonary fibrosis with single lung transplant versus non-transplanted patients: a retrospective observational study. Issue 1 (21st June 2020)

9. Characteristics of lung cancer in idiopathic pulmonary fibrosis with single lung transplant versus non-transplanted patients: a retrospective observational study. Issue 1 (21st June 2020)

10. Characteristics of lung cancer in idiopathic pulmonary fibrosis with single lung transplant versus non-transplanted patients: a retrospective observational study. Issue 1 (21st June 2020)